Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
Trump Pushes $100 Billion U.S. Oil Investment Plan for Venezuela After Maduro Seizure 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Walmart to Join Nasdaq-100 Index as It Replaces AstraZeneca Following Exchange Move 
SAN DIEGO, March 29, 2017 -- Cidara Therapeutics, Inc. (Nasdaq:CDTX), a biotechnology company developing novel anti-infectives including immunotherapies, will host an Investor Day on Thursday, April 6, 2017, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m. PDT) in New York City. Jeffrey Stein, Ph.D., president and chief executive officer, and other members of the Cidara management team, will provide a comprehensive corporate update. In addition, notable infectious disease experts will discuss their perspectives on the anti-infective space.
Interested parties may access a live audio webcast and slides of the presentations on the investor section of Cidara’s website at www.cidara.com beginning at 8:30 a.m. EDT. An archive of the webcast will be available shortly after the event and can be viewed at the same link for a limited time.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing new anti-infectives that have the potential to transform the standard of care and save or improve patients’ lives. The company is currently advancing its novel echinocandin antifungal, CD101 IV, through a Phase 2 study and developing CD201, its bispecific antimicrobial immunotherapy, for the treatment of multi-drug resistant Gram-negative bacterial infections. CD101 IV has enhanced potency and is the only once-weekly therapy intended for the treatment and prevention of life-threatening invasive fungal infections. CD201 is the first drug candidate selected from Cidara’s novel Cloudbreak™ platform, the first immunotherapy discovery platform designed specifically to create compounds that direct a patient’s immune cells to attack and eliminate bacterial, fungal or viral pathogens. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT: Robert H. Uhl Westwicke Partners, LLC Managing Director (858) 356-5932 [email protected] MEDIA CONTACT: Christy Curran Sam Brown Inc. (615) 414-8668 [email protected]
